Choline kinase α activates the mitogen-activated protein kinase pathway by binding and positively regulating epidermal growth factor receptor, thereby enhancing the proliferative, migrative, and ...

The firm will use the funding to begin a pivotal study of its EGFR inhibitor, advance the Phase I study of its CLK inhibitor, and develop its preclinical pan-KRAS program.

Treating glioblastoma with a class of drugs known as EGFR inhibitors made this cancer more sensitive to chemotherapy, ...

Targeted therapies have transformed the treatment landscape for non-small cell lung cancer (NSCLC) over the past decade, particularly for patients whose tumours harbour mutations in the epidermal ...

Many cases are driven by mutations in the EGFR gene, which causes cells to grow and divide uncontrollably. In Southeast Asia, these mutations are found in up to 40–60% of a common type of lung cancer ...

The epidermal growth factor receptor (EGFR) inhibitors are among the most intensely studied new molecular therapeutic agents. Although response rates have been somewhat disappointing when EGFR ...

Researchers at the Medical University of Vienna have described a mechanism in metastatic colorectal cancer that has received little attention to date: A key target of existing therapies, the so-called ...

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, today announced compelling interim safety data from its ongoing Phase 1 ...